Myeloma Genomics and Microenvironment and immune profiling

(PA-203) Ultra-deep, Cost-efficient Whole-genome Sequencing of Cell Free DNA Recovers Most Bone Marrow Mutations in Newly Diagnosed Multiple Myeloma

(PA-208) Multi-Omic Profiling of NK Cell Dysfunction and Tumor Immune Escape in Multiple Myeloma Evolution

(PA-209) Single Cell RNA and Whole Genome Sequencing Analysis Reveal Distinct Immune and Genomic Signatures in WM Patients Resistant to Ibrutinib Therapy

(PA-213) Single-Cell Transcriptomic Stratification of Multiple Myeloma Reveals Oxidative Stress-Driven Subtypes and Cytogenetic Correlates

(PA-215) Defining a Novel Cytokine Combination to Optimize In Vitro Culture Conditions for Primary Multiple Myeloma Patient Cells

(PA-216) The PBX1 Protein Is Substantially Overexpressed in Patients with Multiple Myeloma Exhibiting Chromosomal 1q Gain or Amplification, and It Is Associated with Unfavorable Prognosis

(PA-218) Bortezomib, Lenalidomide, and Dexamethasone Reverses the Inferior Prognostic Effect of KRAS Mutation in Patients with Newly-diagnosed Multiple Myeloma

(PA-219) CD69+ Bone Marrow-Resident CD8+ T Cells Exhibit Functional Exhaustion and Impaired Anti-Tumor Activity in Multiple Myeloma

(PA-220) Integrated Multi-omic Profiling of Immune, Soluble, and Microbial Signatures Identifies Predictors of Multiple Myeloma Evolution

(PA-222) Dissecting B Cell Landscape and Receptor Repertoire in Plasma Cell Neoplasms at Single Cell Resolution

(PA-223) GPRC5D and BCMA Genotypes in Relation to Diagnosis, Prognosis and Lenalidomide-based Maintenance Therapy in Multiple Myeloma Patients

(PA-224) Referral of Select Multiple Myeloma Patients for Genetic Evaluation Leads to 5-Fold Increase in Pathogenic Germline Variant Detection

(PA-227) Characterizing the Molecular Impact of DIS3 Mutation-Driven Mechanisms in Multiple Myeloma

(PA-228) A Novel Hypoxia Gene Signature from the HOVON-65/GMMG-HD4 Phase 3 Study Prognostic of Survival and Associated with Immune Suppression in the Tumor Microenvironment

(PA-230) Exploration of Tumor Immune Gene Expression to Stratify Progression Risk in Newly Diagnosed Multiple Myeloma Patients from CoMMpass with 1q Cytogenetic Abnormality

(PA-234) Integrating Microenvironment with Tumor Multi-Omic using Unsupervised Machine Learning to Model Heterogeneity Refines Multiple Myeloma Subtypes and Reveals Immune-Based Clusters with Prognostic Impact

(PA-239) Onco-miR-148a Expression and Its Function in Multiple Myeloma

(PA-240) Integrative Genetic Profiling of Circulating Tumour DNA And Bone Marrow for Multiple Myeloma Prognostication

(PA-243) Role and Mechanism of Multiple Myeloma Cells in Regulating Macrophage Polarization and the Antitumor Effect via ENO1

(PA-244) Targeting PIM-2 and PARP1 Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells Through NKG2D Binding

(PA-245) Targeting Lactate Metabolism in Multiple Myeloma to Enhance CAR-T Cells Antitumor Function

(PA-249) Contribution of ARID1A Mutations in the Development of Extramedullary Plasmacytoma

(PA-250) Systematic Assessment of MYC by Fluorescence in situ Hybridization in Multiple Myeloma Identifies a High-Risk Population Independent of Other Risk Factors

(PA-251) A Single-Cell Coding and Noncoding Transcriptomic Atlas Reveals ncRNA-Driven Remodeling of the Bone Marrow Microenvironment in Multiple Myeloma

(PA-258) Mapping Cell-Cell Communication Dynamics Across the Spectrum of Multiple Myeloma Evolution Using Single-Cell Transcriptomics.

(PA-261) Comparison of NGS-Based PlasmaSeq and FISH for Routine Genomic Testing in Multiple Myeloma

(PA-262) Single-Cell Transcriptomic Profiling Reveals Immune Aging and Tumor Microenvironment Imprinting in Smoldering Multiple Myeloma

(PA-264) Treatment of Plasma Cell Disorders Post Solid Organ Transplant – A Positive Single Center Experience using Immunomodulatory Drugs

(PA-268) A Vicious Cycle Between Sensory Nerve Outgrowth and Myeloma Tumor Progression in the Bone Marrow

(PA-269) Combining FISH and CMA Improves the Yield of Detection of 17p Deletion in Myeloma

(PA-270) Spatial Transcriptomics Profiling Reveals Resistance Mechanisms in Extramedullary Myeloma Plasmacytomas Following CAR T-cell Therapy

(PA-272) Dual Roles of IRE1α Inhibition in Reversing Mitochondrial ROS-Induced CD8+ T Cell Senescence and Exerting Direct Anti-Tumor Effects in Multiple Myeloma

(PA-273) Insights into Ubiquitination-Associated Genes in Multiple Myeloma: A Multi-Omics Mendelian Randomization Study

(PA-277) Crosstalk Between m6A and H3K27ac via the YTHDC1-EP300 Feedback Loop Promotes Myelomagenesis

(PA-278) NAMPT in Myeloma-Associated Macrophages Drives Drug Resistance through Mitochondrial Metabolic Reprogramming and Immune Evasion via the SIRT1/STAT3/SPP1 Axis

(PA-279) NEDD4-1-Mediated Ubiquitination of CCR7 Reprograms Macrophage Function and Enhances theraputic Sensitivity in Multiple Myeloma.

(PA-280) The m5c-binding Protein YB-1 Modulates Proteasome Inhibitors Resistance in Multiple Myeloma via Epigenetic Modification